...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Convertible Debenture

On May 6th (filed on SEDAR May 7th), Zenith transacted a convertible debenture deal worth $701,600 CAD. The deal was done in US dollars so probably not a Canadian party. It was for 500 convertible debentures @ $1403.20 CAD so since it was done in USD, probably $1000 USD each. It appears that it runs to May 6th, 2022 and is convertible into units of common shares and warrants until that date @ 2.81 CAD (probably $2.00 USD). It did not give a warrant ratio. Warrants are exercisable until May 6, 2022 @ $2.81 CAD (probably $2.00 USD). I have a request in to Zenith for more complete information. 

Share
New Message
Please login to post a reply